ClinicalTrials.gg
CompletedNCT00615615Updated Jul 30, 2020

Efficacy and Tolerability of Levetiracetam Add-On Treatment in Refractory Pediatric Patients With Partial Onset Seizures

A Phase 3 interventional study of Levetiracetam and Placebo in Epilepsy, sponsored by UCB Pharma. Completed. Open to participants aged 4 Years to 16 Years. Per ClinicalTrials.gov, last updated 2020-07-30.

Sponsored by UCB Pharma (part of UCB S.A.) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Registered 8 years 4 months after the study started (first participant enrolled Sep 1999, registered Jan 2008).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
216
Allocation
Randomized
Ages
4 Years to 16 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 60 studies testing levetiracetam in Epilepsy — 4 open to participants now, 4 under way, 2 of them phase 3. Levetiracetam · Epilepsy.

Enrollment
16th of 60
216 · median 94
Started
1999
the only one that year
Phase 3
28 of 60
2 open now
Registered
28th of 60
by date
Lead sponsor
23 of 60
UCB Pharma

Among the 60 studies testing levetiracetam in Epilepsy, this one is the 16th largest by enrollment, is the only one that started in 1999, is one of 28 in phase 3, and was the 28th registered.

Epilepsy

1,848 studies on the registry are indexed under Epilepsy; 419 are open to participants now.

Browse Epilepsy studies →

Open to participants now

4 of the 60 studies testing levetiracetam in Epilepsy are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

About levetiracetam

Levetiracetam: first FDA approval 1999 (KEPPRA), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Epilepsy studies recruiting now, 114 (40%) set no upper age limit and 147 (52%) stop at 75 or younger; 139 take children under 18; 55 take healthy volunteers.

This study: 4 Years to 16 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 60 studies testing levetiracetam in Epilepsy, or all of them as a file.
02

Study summary

Double-blind, randomized, placebo-controlled, multi-center clinical trial conducted to evaluate levetiracetam as adjunctive therapy in children (4-16 years) with refractory partial onset seizures.

03

Conditions studied

  • Epilepsy

Browse trials for

Keywords

  • Levetiracetam
  • Keppra
04

Who can participate

Ages eligible
4 Years to 16 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • diagnosis of epilepsy with uncontrolled partial onset seizures, whether or not secondarily generalized, and the diagnosis was >= 6 months before the Selection Visit
  • epilepsy was classifiable according to the ILAE Classification
  • >= 4 partial onset seizures during the 4 weeks preceding the Selection Visit and were required to have >= 4 partial onset seizures during each 4-week interval of the Baseline Period to qualify for randomization
  • unsatisfactory current AED treatment in terms of efficacy and/or safety
  • stable AED treatment consisting of no more than two AEDs

Exclusion criteria

Exclusion Criteria:

  • treatable seizure etiology
  • epilepsy secondary to a progressive cerebral disease or any other progressively neurodegenerative disease, including Rasmussen and Landau-Kleffner diseases
  • history of status epilepticus which required hospitalization during 3 months prior to the Selection Visit
  • history of or the presence of pseudo seizures
  • current diagnosis of Lennox-Gastaut syndrome
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
216 participants (actual)

Study arms

  • Experimental
    Levetiracetam (LEV)

    LEV dose was titrated to a level of 60 mg/kg/day. The initial dose level was 20 mg/kg/day for the first two weeks, followed by a dose level of 40 mg/kg/day for two weeks. If lower doses were well tolerated, the LEV dose was increased to a dose level of 60 mg/kg/day for the remaining 10 weeks. The dose level could be reduced to 40 mg/kg/day if the patient did not tolerate LEV at a dose level of 60 mg/kg/day.

    Drug: Levetiracetam

  • Placebo comparator
    Placebo

    Subjects received Placebo matching to LEV treatment.

    Drug: Placebo

Interventions

  • * high total tablet weight (HTTW) formulation in tablet strengths of 166.5 mg, 250 mg, and 500 mg was used for patients weighing at least 40.1 kg * low total tablet weight (LTTW) formulation in tablet strengths of 166 mg and 250 mg was used for patients weighing 40 kg or less

  • DrugPlacebo

    Placebo tablets for oral administration that were identical in appearance to the respective formulations (LTTW and HTTW) were used as reference therapy

06

What researchers measure

Primary outcomes

  1. Partial onset seizure frequency (Type I, Type IC included) per week during the Treatment period

    Calculated as 7-day partial onset seizure frequency.

    Time frame: During the 14-weeks Treatment period (Week 8 to Week 22)

Secondary outcomes

  1. 50% responder rate in seizure frequency per week during the Treatment Period

    Response rate is defined as percent of patients experiencing at least a 50% reduction from baseline in the seizure frequency per week during the Treatment Period.

    Time frame: During the 14-weeks Treatment period (Week 8 to Week 22)

  2. Percent of patients with categorized reduction from baseline in seizure frequency per week during the Treatment Period

    Categories as follows: \<-25%, -25% to \<25%, 25% to \<50%, 50% to \<75%, 75% to \<100%, and 100%

    Time frame: From Baseline to the 14-weeks Treatment period

  3. Change from baseline in the average duration of seizure free intervals

    Intervals are defined as seizure-free if no seizures are reported.

    Time frame: From Baseline to the 14-weeks Treatment period

  4. Number of seizure free days during the Treatment Period

    A day is regarded as seizure-free if no seizures are reported.

    Time frame: During the 14-weeks Treatment period (Week 8 to Week 22)

  5. Absolute change from baseline in partial onset seizure frequency per week during the Treatment Period

    Absolute change from baseline in partial onset seizure frequency during the Treatment Period standardized to 1 week period. A negative value in absolute change from baseline indicates a decrease in partial onset seizure frequency from baseline.

    Time frame: Baseline, During the 14-weeks Treatment period (Week 8 to Week 22)

  6. Absolute change from baseline in partial onset seizure frequency per week during the Titration Period

    Absolute change from baseline in partial onset seizure frequency during the Titration Period standardized to 1 week period. A negative value in absolute change from baseline indicates a decrease in partial onset seizure frequency from baseline.

    Time frame: Baseline, During the 6-weeks Titration period (Week 8 to Week 14)

  7. Absolute change from baseline in partial onset seizure frequency per week during the Evaluation Period

    Absolute change from baseline in partial onset seizure frequency during the Evaluation Period standardized to 1 week period. A negative value in absolute change from baseline indicates a decrease in partial onset seizure frequency from baseline.

    Time frame: Baseline, During the 8-weeks Evaluation period (Week 14 to Week 22)

  8. Percent change from baseline in partial onset seizure frequency per week during the Treatment Period

    Percent change from baseline in partial onset seizure frequency during the Treatment Period standardized to 1 week period. A negative value in absolute change from baseline indicates a decrease in partial onset seizure frequency from baseline.

    Time frame: Baseline, During the 14-weeks Treatment period (Week 8 to Week 22)

  9. Percent change from baseline in partial onset seizure frequency per week during the Titration Period

    Percent change from baseline in partial onset seizure frequency during the Titration Period standardized to 1 week period. A negative value in absolute change from baseline indicates a decrease in partial onset seizure frequency from baseline.

    Time frame: Baseline, During the 6-weeks Titration period (Week 8 to Week 14)

  10. Percent change from baseline in partial onset seizure frequency per week during the Evaluation Period

    Percent change from baseline in partial onset seizure frequency during the Evaluation Period standardized to 1 week period. A negative value in absolute change from baseline indicates a decrease in partial onset seizure frequency from baseline.

    Time frame: Baseline, During the 8-weeks Evaluation period (Week 14 to Week 22)

  11. Cumulative percentage of patients who were seizure-free since the beginning of the Evaluation Period

    A subject was regarded as seizure-free if not seizures were reported since the beginning of the Evaluation Period.

    Time frame: Beginning of the Evaluation Period (Week 14)

  12. Partial onset seizure frequency per week during the Titration Period

    Calculated as 7-day partial onset seizure frequency.

    Time frame: During the 6-weeks Titration period (Week 8 to Week 14)

  13. Partial onset seizure frequency per week during the Evaluation Period

    Calculated as 7-day partial onset seizure frequency.

    Time frame: During the 6-weeks Evaluation period (Week 8 to Week 14)

  14. Total seizure frequency per week (Types I + II + III) during the Treatment Period

    Calculated as 7-day partial onset seizure frequency.

    Time frame: During the 14-weeks Treatment period (Week 8 to Week 22)

  15. Total seizure frequency per week (Types I + II + III) during the Titration Period

    Calculated as 7-day partial onset seizure frequency.

    Time frame: During the 6-weeks Titration period (Week 8 to Week 14)

  16. Total seizure frequency per week (Types I + II + III) during the Evaluation Period

    Calculated as 7-day partial onset seizure frequency.

    Time frame: During the 6-weeks Evaluation period (Week 8 to Week 14)

07

Study locations

No study locations are listed for this record.

08

References and documents

Publications

  • Glauser TA, Ayala R, Elterman RD, Mitchell WG, Van Orman CB, Gauer LJ, Lu Z; N159 Study Group. Double-blind placebo-controlled trial of adjunctive levetiracetam in pediatric partial seizures. Neurology. 2006 Jun 13;66(11):1654-60. doi: 10.1212/01.wnl.0000217916.00225.3a. Epub 2006 Apr 26. PubMed 16641323 ↗
  • Jensen FE, Bourgeois BF. Randomized trial supports use of levetiracetam adjunctive therapy to treat partial seizures in children. Nat Clin Pract Neurol. 2006 Nov;2(11):596-7. doi: 10.1038/ncpneuro0325. No abstract available. PubMed 17057745 ↗
  • Johnson ME, McClung C, Bozorg AM. Analyses of seizure responses supportive of a novel trial design to assess efficacy of antiepileptic drugs in infants and young children with epilepsy: Post hoc analyses of pediatric levetiracetam and lacosamide trials. Epilepsia Open. 2021 Jun;6(2):359-368. doi: 10.1002/epi4.12482. Epub 2021 May 3. PubMed 34033237 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 1999 to primary completion in Mar 2003, 42 months.

Of 66 industry-sponsored phase 3 interventional studies under Epilepsy, half reached primary completion within 48 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 70. This study's 42 months is below that.

Counting every sponsor, half of 85 studies reached it within 48 months; a quarter within 29 and three quarters within 69.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 27, 2008
First posted
Feb 14, 2008
StartActual
Sep 1999
Primary completionActual
Mar 2003
CompletionActual
Mar 2003
Last update
Jul 30, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 30, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00615615
Lead sponsor
UCB Pharma
First posted
Feb 14, 2008
Start date
Sep 1999
Primary completion
Mar 2003
Completion
Mar 2003
Last update
Jul 30, 2020

Study contacts

UCB Cares
study director · +1 844 599 2273 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Levetiracetam

Start the discussion